Alternative Search Engine

Novelion Therapeutics: Recent Licensing Deal Reignites The Stock And Has Me Debating A Buy

Source:   ( Money & Markets > Investments > Stocks )

Feb 12, 2019 3:58 PM 1+ week ago

Novelion recently announced their licensing deal with Recordati for commercial rights to JUXTAPID in Japan. This deal provides Novelion with immediate and long-Read more.

Search Builder

(Click to add to search box)
Search Suggestions Level 1
Novelion Therapeutics  press release  upfront payment  sales milestone payments  bridge credit agreement  cash position  Highbridge Capital Management  Athyrium Capital Management  Mitigation Strategies REMS  Alpha Summary Novelion  Downside Risk  licensing deal  milestone payments  market cap  hypercholesterolemia HoFH  market conditions  sales activities  commercialization deal  FDA process  NVLN Worth  heart attack  market rebound  NVLN chart  takeaway message  Risk Evaluation  Fast Money  settlement payments  news release  warning letter  financing facility  license agreement  compliance efforts  Cash Position  intercompany loan  cash proceeds  Recordati payment  November financing  Regulatory Action  Uncovering Details  licensing deals  payment plan  debt extension  downside risks  label expansion  annum rate  CIA program  company executives  lipodystrophy GL  MYALEPT MYALEPT  LDL cholesterol  steatohepatitis NASH  Recordati deal  game plan  company nothing  analyst coverage  commercialization rights  monitoring NVLN  lipodystrophy PL  drug JUXTAPID  disease space  licensing agreement  Aegerion Pharmaceuticals  insurance plan  Recordati Deal  insurance coverage  concerns emanate  
Search Suggestions Level 2
stock deal  Halifax firm Appili  TSX Antibe Therapeutics  Novelion Therapeutics  Fate Therapeutics  Recent Deal  United Therapeutics  
Search Suggestions Level 3
ONO Pharmaceutical Co  Senior Vice President  cancer relapse  licensing Asia rights  Wen Bo Wang  capital pool company  New Drug Application  Cell Therapy Research  Cantor presentation  CAR T cells  chimeric antigen receptor  TrepT drug candidate  hematopoietic cell graft  FUJIFILM Cellular Dynamics  Toronto Stock Exchange  United Therapeutics treatments  Technosphere treatment space  PROTECT study  stock deal  risk factors  NK cells  PAH treatment  feedback matters  business relationship  novel drug  vice president  need metronidazole  efficacy signals  APOLLO trials  patient cells  neutrophil engraftment  cell therapies  patent applications  cell therapy  TrepT product  company check  investor event  future catalysts  reality check  endpoint freedom  Cancer meeting  flagship product  rescue therapy  bull thesis  IND application  Technosphere compounds  market price  inhaled delivery  life support  Arena deal  way guarantee  investment decisions  index funds  Year ROTY  industry veterans  Catalyst Tracker  Live Chat  MannKind coverage  Jonathan Faison  PAH franchise  PAH space  Arena Pharmaceuticals  United Therapeutics  news reactions  inked partnership  T cells  flagship drug  cytokine production  antigen specificity  future collaborations  Redmile Group  manufacturing facilities  Final Thoughts  offering dilution  product candidates  safety issues  General Dynamics  Wells Fargo  development expenses  apple sauce  metronidazole tastes  manufacturing activities  licensing activities  patient access  company plans  target children  shell company  Peter Moreira  immunotherapy pioneer  Recent Developments  DIMENSION study  antibody therapy  Last October  product candidate  Sean McBride  business development  Jamie Doran  drug development  Kimberly Stephens  Ryan Tobin  drug candidate  couldn t  

**Content contained on this site is provided on an “as is” basis. 4Internet, LLC makes no commitments regarding the content and does not review it, so don't assume that it's been reviewed. What you see here may not be accurate and should not be relied upon. The content does not necessarily represent the views and opinions of 4Internet, LLC. You use this service and everything you see here at your own risk. Content displayed may be subject to copyright. Content is removed on a case by case basis. To request that content be removed, contact us using the following form: Contact Us.